Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 139,741	$ 129,942
Marketable securities	245	3,306
Accounts receivable, net of allowance for doubtful accounts of $120 and $120, respectively	30,384	70,758
Other receivables	12,572	5,489
Inventories	4,176	9,200
Prepaid expenses and other assets	4,206	3,774
Total current assets	191,324	222,469
Property and equipment, net of accumulated depreciation	918	1,405
Intangible assets, net of accumulated amortization	190,335	230,100
Goodwill	17,960	18,195
Other assets	20,683	17,864
Total assets	421,220	490,033
Current liabilities:
Accounts payable and other accrued liabilities	56,539	84,994
Accrued payroll and benefits	8,188	8,444
Deferred revenue	6,130	9,959
Drug development liability	259	1,141
Acquisition-related contingent obligations	5,227	4,901
Total current liabilities	76,343	109,439
Drug development liability, less current portion	14,427	14,644
Deferred revenue, less current portion	383	0
Acquisition-related contingent obligations	1,439	2,441
Deferred tax liability	6,779	6,569
Other long-term liabilities	7,444	6,088
Convertible senior notes	101,548	96,298
Total liabilities	$ 208,363	$ 235,479
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.001 par value; 175,000,000 shares authorized; 68,228,935 and 65,969,699 issued and outstanding at December 31, 2015 and 2014, respectively	$ 68	$ 66
Additional paid-in capital	552,108	538,553
Accumulated other comprehensive loss	(5,319)	(850)
Accumulated deficit	(334,123)	(283,338)
Total stockholders’ equity	212,857	254,554
Total liabilities and stockholders’ equity	421,220	490,033
Series B Preferred Stock [Member]
Stockholders’ equity:
Preferred stock	0	0
Series E Convertible Voting Preferred Stock [Member]
Stockholders’ equity:
Preferred stock	$ 123	$ 123